Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Progyny reports mixed Q3 performance, focuses on client growth

Progyny faced challenges in member activity and gross margin in Q3 2024.
Despite this, positive selling season results and strong client commitments were noted.
Renewals and upsell activities remained robust, supporting revenue guidance.
The company's focus on care management services and cash flow stability is evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This fertility stock could have serious long-term potential.

Here's Why Investors Should Put Progyny on Their Radar

BlackBerry

Tilray Brands

Five9

Nio, BlackBerry, Tilray, Five9 and Progyny were our top stock trades for Tuesday. Let's check out the charts after a long holiday weekend.

5 Top Stock Trades for Tuesday: NIO, FIVN, TLRY, PGNY, BB

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced the appointment of two new members to its board of directors, effective November 16, 2020. Joining the board are Malissia R. Clinton, Senior Vice President, General Counsel, and Secretary of The Aerospace Corporation and Roger Holstein, Managing Director of Vestar Capital Partners.

Progyny Strengthens Board of Directors with Appointments of Healthcare and Technology Leaders

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny's Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Progyny, Inc. Announces Participation at the Piper Sandler Healthcare Conference

Progyny, Inc. (PGNY) CEO David Schlanger on Q3 2020 Results - Earnings Call Transcript

Progyny went public in October 2019, raising $130 million. The firm provides fertility and family planning benefit services in the United States.

Progyny Grows Business But Stock May Be Priced For Perfection

Progyny (PGNY) delivered earnings and revenue surprises of 0.00% and 6.18%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Progyny (PGNY) Q3 Earnings Meet Estimates

Shares of Progyny (NASDAQ:PGNY) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 66.67% over the past year to $0.05, which were in line with the estimate of $0.05.

Progyny: Q3 Earnings Insights

NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period ended September 30, 2020 after the close of the market on Thursday, November 5, 2020.

Progyny, Inc. Announces Details for Its Third Quarter Results Report

Pharmacy benefits manager Progyny Inc (NASDAQ: PGNY) is trading 8.22% lower on thin volume in the pre-market session on Thursday. The company disclosed in SEC form 4 that TPG Group Holdings, who are more than 10% owners in the company, sold 72,768 shares pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III.

Why Progyny's Stock Is Trading Lower In Pre-Market Session

Researchers Studied Journey Level Analysis of Progression to Treatment Versus Drop Out in a Large Cohort of Patients with Access to a Defined Fertility Benefit Researchers Studied Journey Level Analysis of Progression to Treatment Versus Drop Out in a Large Cohort of Patients with Access to a Defined Fertility Benefit

Progyny and RMA of New York Partner on Original Research Selected for Presentation at the 76th Annual ASRM Scientific Congress and Expo

DraftKings

Intuitive Surgical

Lululemon Athletica

Monster Beverage

Pinterest

Fastly

There are a handful of companies with no debt in the stock market, but not all of them are worth a close look. Here are seven that are.

7 Debt-Free Stocks to Buy For Peace of Mind In Volatile Markets

NEW YORK, Sept.  10, 2020  (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that David Schlanger, Progyny’s Chief Executive Officer, will participate in a fireside chat at the BofA Global Healthcare Conference on Thursday, September 17, 2020 at 11:45 A.M. Eastern Time, or 4:45 P.M. British Summer Time.

Progyny, Inc. Announces Participation at the BofA Global Healthcare Conference

Progyny provides employers with fertility benefits to help their employees build families.

This Company Is Winning in the Fast-Growing Fertility Benefits Industry

Livingston Will Continue Reporting to Pete Anevski, Progyny’s President and Chief Operating Officer Livingston Will Continue Reporting to Pete Anevski, Progyny’s President and Chief Operating Officer

Progyny, Inc. Promotes Seasoned Executive Mark Livingston to Chief Financial Officer

Aphria

CrowdStrike

Inmode Ltd

The RealReal

Roku

Virgin Galactic

Slack

Growth stocks have been the market's biggest winners. Amid valuation concerns, these 10 stocks still have the potential for 100%-plus gains.

10 Growth Stocks That Could Seriously Double

Progyny, Inc's (PGNY) CEO David Schlanger on Q2 2020 Results - Earnings Call Transcript

Reports Second Quarter Revenue of $64.6 MillionPatient Return to Treatment Faster Than ExpectedIssues Revenue Guidance of $323.0 to $340.0 Million for Full Year 2020, Reflecting Growth of 41% to 48%Issues Revenue Guidance of $88.0 to $95.0 Million for the Third Quarter of 2020, Reflecting Growth of 44% to 55%

Progyny, Inc. Announces Second Quarter 2020 Results

Progyny Is Delivering Even During Lockdown

NEW YORK, July  22, 2020  (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period ended June 30, 2020 after the close of the market on Wednesday, August 5, 2020.

Progyny, Inc. Announces Details for Its Second Quarter Results Report

Progyny: In Its Third Trimester And Poised For Healthy Growth

Q1 earnings beat, and Progyny is lining up to do it again in Q2.

Why Progyny Stock Popped 27%

Progyny, Inc. (PGNY) CEO David Schlanger on Q1 2020 Results - Earnings Call Transcript

Company Well-Positioned to Successfully Manage COVID-Related Impacts Reports 72% Increase in First Quarter Revenue to $81.0 MillionReports $12.1 Million in Quarterly Operating Cash Flow, Adding to its Already Strong Balance Sheet

Progyny, Inc. Announces First Quarter 2020 Results

Progyny reports earnings after the close today as fertility clinics postpone procedures due to the coronavirus pandemic.
The post Progyny Reports Earnings Late As Coronavirus Delays Fertility Services appeared first on Investor's Business Daily.

News for Progyny Stock (PGNY)